

Evolocumab

产品编号：MB2797

质量标准：>95%,蛋白原液

包装规格：1MG/5MG

产品形式：

基本信息

分子式	C6242H9648N1668O1996S56
分子量	141.80KD
CAS NO	1256937-27-5
储存条件	-70 ± 15°C for long-term storage, 2-8°C for short-term storage, away from light

简介： Evolocumab is a monoclonal antibody as well as an inhibitor of proprotein convertase subtilisin/kexin type 9 (PCSK9), a protein targeting LDL receptors. Inhibition of PCSK9 could prevent LDL receptors from degradation and promote the removal of LDL-C from blood circulation. Evolocumab is used for the treatment of hyperlipidemia.

产品形式： 蛋白原液。每种装于冻存管中，单抗质量为标示数量 1MG 或者 5MG，体积根据其浓度不同略有不同。

质量标准：

Non-reduced CE-SDS:.....>90%;

SEC-HPLC:.....>95%;

Bacterial Endotoxins Test:<10EU/ml

Residual Proteins of HostCell:<100 ng/mg

Exogenous residual DNA:<100pg/mg

Residual Protein A:<100 ng/mg

Biological Activity:.....80% to 125% of standard

储存条件： -70 ± 15°C for long-term storage, 2-8°C for short-term storage, away from light.

使用建议：

meilunbio 提供的产品为蛋白原液形式。每种装于冻存管中，单抗质量为标示数量 1MG 或者 5MG，体积根据其浓度不同略有不同。

使用前可以根据自己实验需求进行稀释，溶剂建议用去离子无菌水(meilunbio 货号 MA0028，去离子无菌水(细胞培养用水))或者 PBS (meilunbio 货号 MA0015PBS(1X),细胞培养级)。

不建议使用含有防腐成分的稀释液进行稀释，会增加细胞或者动物毒性。

稀释前，计算加入多少体积溶剂，请参考购买批次质检单上蛋白浓度，或者询问我司，

举例，质检单显示该批次单抗蛋白原液蛋白浓度为 50mg/ml

对应 5MG 包装的蛋白原液体积为 5mg（质量）/50mg/ml(浓度)=0.1ML，

实验需求蛋白浓度为 10mg/ml, 需要稀释倍数为 50/10=5, 则需要加入 0.4ML,即 400ul PBS 或者无菌去离子水即可。

若给药量为固定质量值，比如单次给药 0.5MG，对应蛋白原液给药体积为 10ul，建议稀释后，提高给药体积降低误差，因为注射器或者移液器吸头残留会影响实验效果。

稀释后的蛋白溶液，可于 2-8 度冷藏避光保存不超过 2 周，不建议长期储存。

避免反复冻融，每次冻融蛋白活性会降低约 5%左右。

生物活性（仅来自于公开文献，不保证其有效性）

描述	Evolocumab is a human IgG2 monoclonal antibody that binds to human PCSK9 (ProproteinConvertase SubtilisinKexin Type 9).
靶点	PCSK9,
体内	In mice, a single intravenous injection of evolocumab 10 mg/kg reduced total cholesterol by 20, 26, and 28% at 24, 72, and 144 h after injection, respectively . The magnitude and duration of the effects of evolocumab were dose related: total cholesterol at 3 days after an injection of evolocumab 3, 6, or 10 mg/kg was reduced from baseline by 26, 28, and 36%, respectively. By day 12, total cholesterol levels in all treatment groups were similar to those in control animals. Reference : Sreeneeranj Kasichayanula, et al. Clinical Pharmacokinetics and Pharmacodynamics of Evolocumab, a PCSK9 Inhibitor. Clin Pharmacokinet. 2018; 57(7): 769–779.

美仑相关产品推荐(更多相关靶点抑制剂请详询官网或客服)

产品编号	品名.	Target
MB2806	aflibercept	VEGFR
MB2786	Alemtuzumab	CD52
MB2787	Alirocumab	PCSK9
MB2789	Avelumab	PDL-1
MB2790	Atezolizumab	PDL-1
MB2791	Bevacizumab	VEGF
MB2792	Cetuximab	EGFR
MB2803	Daratumumab	CD38
MB2794	Denosumab	RANK Ligand
MB2023	Eculizumab	补体蛋白(C5)

MB2795	Etanercept	TNF
MB2784	Adalimumab	TNF- α
MB2773	Infliximab	TNF- α
MB2769	Ipilimumab	CTLA-4
MB2772	Matuzumab	EGFR
MB2766	Mepolizumab	IL-5
MB2767	Nivolumab	PD-1
MB2774	Obinutuzumab	CD20
MB2776	Ofatumumab	CD20
MB2777	Omalizumab	IgE
MB2781	Panitumumab	EGFR
MB2761	Pembrolizumab	PD-1
MB2762	Pertuzumab	HER2
MB2763	Ranibizumab	VEGFR
MB2938	Ramucirumab	VEGFR
MB2749	Rituximab	CD20
MB2757	Secukinumab	IL-17
MB2751	Tocilizumab/Atlizumab	IL-6 receptor
MB2753	Trastuzumab	ErbB2
MB2758	Ustekinumab	IL-12

用途及描述: 仅供科研, 严禁用于人体(For R&D Only)